BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

LAM Pharmaceutical Corporation (LAMP) Announces Official Launch Of LAM IPM Wound Gel(TM) In Ecuador


10/19/2005 5:12:59 PM

LEWISTON, N.Y., March 10 /PRNewswire-FirstCall/ -- LAM Pharmaceutical, Corp. (OTC Bulletin Board: LAMP; Frankfurt: LAM; Berlin: LAM), a biomedical company focused on the development and commercialization of novel wound healing and transdermal drug delivery systems, announced today that a series of official launch presentations of the LAM IPM Wound Gel(TM) in Ecuador will take place the week of April 18, 2005.

Mr. Diego Pesantez, General Manager of aQva Pharmaceuticals Inc in Ecuador, stated, "I am looking forward to introducing the LAM IPM Wound Gel(TM) to our major urban markets, namely Quito, Cuenca and Guayaquil. We anticipate initial sales demand from private medical sector to be at least 1000 units per month. Furthermore, we have initiated the process of including LAM IPM Wound Gel(TM) on the Cuadro Basico (Ecuador's national government formulary). The listing of the Gel in the Cuadro Basico will add significantly to the sales potential."

Mr. Salvador Ficciella, CEO of aQva Pharmaceuticals Inc., commented, "We are very excited to add Ecuador to the list countries actively selling LAM IPM Wound Gel(TM). We are committed to achieving strong market penetration for the Gel in both the private and national health sectors."

Mr. Joseph T. Slechta, President and Chief Executive Officer of LAM, noted, "I am confident that the upcoming Ecuador launch will represent another successful step in our international sales initiatives for the Gel."

About LAM Pharmaceutical, Corp.

L.A.M. Pharmaceutical, Corp., http://www.lampharm.com/, is a biomedical company with offices in Lewiston, New York, Toronto, Canada and Beijing, China. LAM focuses on the development and commercialization of novel wound healing and transdermal drug delivery systems that offer patients, among other benefits, safer and more effective treatment for a variety of serious diseases. The technology is based on an original L.A.M. Ionic Polymer Matrix(TM) technology (L.A.M. IPM(TM)), a proprietary and patented combination (a total of 15 U.S. issued and approved patents) of electrically charged and non-charged molecules with wound-healing properties. L.A.M. IPM(TM) technology is also appropriate for use with well-established drugs, allowing for the sustained delivery of greater amounts to the target areas than is otherwise possible by oral means, thus prolonging therapeutic activity.

About aQva Pharmaceuticals

aQva Pharmaceuticals is an international distribution company with headquarters in Montreal, Canada, an operating subsidiary in Mexico City and distribution partners in several Latin American Countries. aQva main business focus is to distribute pharmaceutical and healthcare products in Latin America.

L.A.M. Ionic Polymer Matrix(TM), L.A.M. IPM(TM) and IPM Wound Gel(TM) are trademarks of L.A.M. Pharmaceutical, Corp.

L.A.M. IPM Wound Gel(TM) is protected by one or more of the following patents: 5,897,880; 6,120,804; 6,007,843; 6,063,405.

Stephanie Carrington (Investors/Media) +1-646-536-7017 The Ruth Group

LAM Pharmaceutical, Corp.

CONTACT: Stephanie Carrington, Investors/Media, +1-646-536-7017, of TheRuth Group for LAM Pharmaceutical, Corp.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES